Biogen (BIIB) closed at $250.69 on October 23, 2026, down 1.2% from the previous close, on volume of 1,092,863 shares (30-day average 1,179,652).
Data as of October 23, 2026.
23-Oct-2026
Business Wire (Thu, 22-Oct 8:00 AM ET)
TipRanks (Thu, 22-Oct 5:50 AM ET)
TipRanks (Tue, 20-Oct 7:40 AM ET)
Wells Fargo Reaffirms Their Buy Rating on Biogen (BIIB)
TipRanks (Tue, 20-Oct 6:56 AM ET)
Wedbush Remains a Hold on Biogen (BIIB)
TipRanks (Tue, 20-Oct 3:25 AM ET)
Biogen’s BIIB147 ALS Trial: A Long-Horizon Catalyst for Neurology Investors
TipRanks (Mon, 19-Oct 12:30 PM ET)
Globe Newswire (Mon, 19-Oct 7:30 AM ET)
Business Wire (Mon, 5-Oct 7:00 AM ET)
Globe Newswire (Fri, 2-Oct 11:20 AM ET)
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Biogen trades on the NASDAQ stock market under the symbol BIIB.
As of October 23, 2026, BIIB stock price declined to $250.69 with 1,092,863 million shares trading.
BIIB has a beta of 0.00, meaning it tends to be less sensitive to market movements. BIIB has a correlation of 0.00 to the broad based SPY ETF.
BIIB has a market cap of $37.01 billion. This is considered a Large Cap stock.
Last quarter Biogen reported $3 billion in Revenue and $3.60 earnings per share. This beat revenue expectation by $314 million and exceeded earnings estimates by $1.25.
In the last 3 years, BIIB traded as high as $268.30 and as low as $110.04.
The top ETF exchange traded funds that BIIB belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
BIIB has outperformed the market in the last year with a price return of +69.7% while the SPY ETF gained +14.9%. BIIB has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +26.8% and +14.8%, respectively, while the SPY returned +1.9% and -1.8%, respectively.
BIIB support price is $248.18 and resistance is $259.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BIIB shares will trade within this expected range on the day.
